Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

June 1, 2028

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
OTHER

Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis

"Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients.~Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence."

Trial Locations (1)

430030

RECRUITING

Tongji Hospital, Wuhan

All Listed Sponsors
lead

Tongji Hospital

OTHER